PsychoGenics Revenue and Competitors

Paramus, NJ USA

Location

#4795

Growjo Ranking

Research

Industry

Estimated Revenue & Valuation

  • PsychoGenics's estimated annual revenue is currently $10.5M per year.(i)
  • PsychoGenics's estimated revenue per employee is $63,289

Employee Data

  • PsychoGenics has 166 Employees.(i)
  • PsychoGenics grew their employee count by 6% last year.

PsychoGenics's People

NameTitleEmail/Phone
1
Chief Commercial Officer (CCO)Reveal Email/Phone
2
SVP, Neurodegenerative DisordersReveal Email/Phone
3
VP, Research & OperationReveal Email/Phone
4
EVP, External Client AffairsReveal Email/Phone
5
VP, Sales & MarketingReveal Email/Phone
6
VP Facilities and OperationsReveal Email/Phone
7
VP, Data Science and EngineeringReveal Email/Phone
8
VP, Veterinary OperationsReveal Email/Phone
9
VP, Translational NeuroscienceReveal Email/Phone
10
General CounselReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.1M297%N/AN/A
#2
$2.6M3219%N/AN/A
#3
$1.2M19-58%N/AN/A
#4
$26.9M24030%N/AN/A
#5
$10.9M1078%N/AN/A
#6
$63.1M535N/AN/AN/A
#7
$57M44710%N/AN/A
#8
$5.7M6244%N/AN/A
#9
$8.1M798%N/AN/A
#10
$49.6M389-67%N/AN/A
Add Company

What Is PsychoGenics?

PsychoGenics, a private biopharmaceutical company, with expertise in the field of behavioral neurobiology, and provider CNS drug discovery solutions to Pharmaceutical and Biotechnology companies, is combining its expertise in behavior with the power of bioinformatics to develop a breakthrough, in vivo preclinical behavioral testing platform. This automated and computerized high-throughput platform offers companies an alternative approach to target discovery and validation, and drug discovery by providing faster, more objective and higher quality results than traditional, subjective manual approaches.

keywords:N/A

N/A

Total Funding

166

Number of Employees

$10.5M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$44.4M1695%N/A
#2
$61.5M1732%N/A
#3
$15M179N/AN/A
#4
$36.4M1843%N/A
#5
$15M2014%N/A